Navigation Links
Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) and Boston Scientific's Taxus(R) Stent in Patients at High Risk of Restenosis
Date:10/22/2007

WASHINGTON, Oct. 22 /PRNewswire/ -- The preliminary results of the first- ever randomized study to compare OrbusNeich's pro-healing stent, the Genous Bio-engineered R stent, with Boston Scientific's Taxus drug-eluting stent in high risk of restenosis patients show comparable efficacy at 30-day and six- month follow-up, reported Robbert de Winter, M.D., Ph.D., principal investigator and director of the catheterization laboratory at the Academic Medical Center in Amsterdam, at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, in Washington, D.C.

Specifically, six-month clinical follow-up data from the 193-patient, single-center, prospective, single-blind study called TRIAS HR Pilot indicate:

-- No statistically significant difference in the rate of major adverse

cardiac events (MACE)

-- At six-month follow-up, the majority of patients who received a Genous

stent were on single antiplatelet therapy, while the majority of

patients who received a Taxus stent were still on dual antiplatelet

therapy

-- One acute stent thrombosis in the Genous arm, while there was one acute,

one subacute and one late stent thrombosis in the Taxus arm

-- More instances of non-target vessel revascularization (non-TVR) in the

Taxus arm

"The much-needed alternative to drug-eluting stents may not be the next- generation drug-eluting stents," said de Winter. "Genous is a very promising, innovative device with a wide range of applications for physicians and many benefits to patients. The results of our pilot study fully support our rationale for the large-scale TRIAS study that will compare Genous to both drug-eluting and bare metal stents."

For the TRIAS HR Pilot, high risk of restenosis is defined as patients who have diabetes mellitus and/or small vessels (less than 2.8 mm) and/or long lesions (greater than 20 mm) and/or chronic total occlusions.

Genous is coated with an antibody to capture a patient's endothelial progenitor cells, and, therefore, accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of the Genous stent, EPCs can form an endothelial layer over the stent to provide protection against thrombus and minimize restenosis. The stent was developed by OrbusNeich, a global medical device company.

For more information, call +31.20.56.67.883 or send an e-mail to trias@amc.nl.

Media Contacts:

David Schull

Russo Partners LLC

+1.212.845.4271 (office)

+1.858.717.2310 (mobile)

david.schull@russopartnersllc.com

Benjamin Carmichael

+1.212.845.4242

benjamin.carmichael@russopartnersllc.com


'/>"/>
SOURCE Academic Medical Center
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
2. Biotec Pharmacon Announces Preliminary Results from the Sloan-Kettering Clinical Study
3. Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
6. Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA
7. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
8. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
9. ISTA Pharmaceuticals Announces Positive Preliminary Results from Ecabet Sodium Phase IIb Study
10. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
11. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
(Date:4/27/2016)... 27, 2016 ... in Zürich gab Strekin AG den Start ... zur Erhaltung des Resthörvermögens von Patienten, denen ... die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan ... wird während der Operation direkt ins Mittelohr ...
Breaking Medicine Technology:
(Date:5/2/2016)... , ... May 02, 2016 , ... According to an ... one in four girls are sexually abused before the age of 18. Of those ... to tell her story and others. , In her new book, Lyah! Lyah! ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... urgent care facilities designed to automate and improve the rapid diagnosis, triage and ... is demonstrating their platform, application, and mobile experience for the first time at ...
(Date:5/2/2016)... ... ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t surprised that Charlotte, NC, the city where ... 5 US Cities with the Highest Plastic Rates .” The other cities that made ... calculated using a survey by RealSelf and combining that data with the number ...
(Date:5/2/2016)... ... ... For many artists, the act of blending paint is based on intuition ... , Using the new, highly precise METTLER TOLEDO ML204T balance to weigh and ... to his works. What’s more, it has allowed him to recreate these shades and ...
(Date:5/2/2016)... ... May 02, 2016 , ... One of Hollywood’s best kept secrets for ... & Laser Center, in Milford, Penn. “Patients with busy lives want noninvasive options for ... and go home or back to work without having to wear recovery garments or ...
Breaking Medicine News(10 mins):